Polypeptide Tesamorelin Human Peptide Steroid Hormones Egrifta CAS 218949-48-5

Description


Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.Tesamorelin (also known as Egrifta) is a synthetic form of growth-hormone-releasing hormone which is used in the treatment of HIV-associated lipodystrophy.tendon fibroblasts in a dose-dependent manner as revealed by transwell filter migration assay.

BPC 157 also dose dependently accelerated the spreading of tendon fibroblasts on culture dishes. The F-actin formation as detected by FITC-phalloidin staining was induced in BPC 157-treated fibroblasts. The protein expression and activation of FAK and paxillin were determined by Western blot analysis, and the phosphorylation levels of both FAK and paxillin were dose dependently increased by BPC 157 while the total amounts of protein was unaltered. In conclusion, BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.
Applications

1. Triptorelin raises testosterone levels by causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH).

2. Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty,estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.

3.Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals.Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism.Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes HGH production and possible fat loss.Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).